Could a tiny coil in the head stop migraines?
NCT ID NCT07633067
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if a procedure called middle meningeal artery embolization can help people with frequent migraines. The procedure uses tiny coils to block a blood vessel in the head. Researchers want to see if it reduces migraine days and the need for migraine medications. The study will include 150 adults aged 18 to 80 who have migraines at least 4 days per month.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 18\~80 years old (inclusive), regardless of gender. 2. Voluntary written informed consent. 3. Migraine diagnosed by neurologists/pain specialists according to the current International Classification of Headache Disorders, 3rd Edition (ICHD-3) criteria for migraine with or without aura. 4. Migraine attack frequency of no less than 4 days per month within one month prior to enrollment. 5. History of pharmacotherapy for migraine prophylaxis or treatment for at least 6 months. Exclusion Criteria: 1. Findings on cerebral angiography indicating secondary headache due to intracranial vascular disorders, including dural arteriovenous fistula, arteriovenous malformation, venous malformation, or other relevant cerebrovascular lesions; Moyamoya disease; or high-risk vascular anatomical variants unsuitable for safe vascular access or contraindicating MMA embolization. 2. Complicated with cervical spondylosis and secondary headache of otogenic, rhinogenic, odontogenic origin; patients with a history of trigeminal autonomic cephalalgias; headache with other definite etiologies or secondary headache; 3. Imaging diagnosis shows acute or chronic subdural hematoma, other acute intracranial lesions and other space-occupying lesions; 4. Patients planning to undergo surgery within 90 days; 5. Patients with a life expectancy of less than 12 months; 6. Patients with a definite history of contrast media allergy; 7. Patients with a history of opioid addiction; 8. Breastfeeding or pregnant women, or patients with fertility plans within half a year; 9. Subjects who participated in other clinical trials of drugs or medical devices before enrollment and did not reach the time limit of the primary study endpoint; 10. Unable to understand headache-related assessment data such as headache diaries and requiring assistance from others to complete them; 11. Patients with poor compliance judged by the investigator and unable to complete the study as required; 12. Patients with a definite history of allergy to embolization materials such as nitinol alloy and/or cobalt-based alloy, platinum-tungsten alloy, etc.; 13. Subjects with other comorbidities that restrict their participation in the study, prevent compliance with follow-up, or affect the scientific integrity of the study; 14. Other conditions in which the investigator considers the patient inappropriate to participate in this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Migraine are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your toothpaste be triggering migraines? trial puts it to the test
- Can sleep, neck pain, and fatigue explain Migraine's daily toll?
- Do Gender-Affirming hormones trigger headaches? thai survey probes the question
- Can a pill stop a migraine in two hours?
- Can tai chi or acupuncture rewire the migraine brain?
- Could a migraine injection also heal caregiver burnout?